What is GeneBeyond?
GeneBeyond is a biopharmaceutical research and development firm dedicated to pioneering new therapies in cancer immunotherapy and tissue regeneration. The company leverages advanced biopharmaceutical platforms, including monoclonal antibody discovery, biologics process development, synthetic biology, and small molecule discovery. GeneBeyond also provides critical technical support for elucidating physiological functions and disease mechanisms, aiding in biomarker and drug target identification. Its services are tailored for clients within the life sciences and biopharmaceutical sectors, aiming to accelerate the development of novel treatments.
How much funding has GeneBeyond raised?
GeneBeyond has raised a total of $43K across 1 funding round:
Debt
$43K
Debt (2021): $43K with participation from PPP
What's next for GeneBeyond?
With significant Series B/C stage funding, GeneBeyond is poised for accelerated growth and the scaling of its operations. The recent capital infusion is expected to fuel further research and development initiatives, potentially expanding its pipeline of cancer immunotherapies and regenerative medicine solutions. This strategic financing will likely enable GeneBeyond to advance its drug candidates through clinical trials and strengthen its market presence, solidifying its role as an innovator in the biopharmaceutical landscape.
See full GeneBeyond company page
